.Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01C_AgentsAgainstLeishmaniasisAndTrypanosomiasis.P01CX03_Eflornithine.Eflornithine

Information

Eflornithine is an antiprotozoal drug primarily used in the treatment of African trypanosomiasis (sleeping sickness), especially caused by Trypanosoma brucei gambiense. It inhibits ornithine decarboxylase, an enzyme involved in polyamine synthesis. Eflornithine is approved for this indication and is on the WHO Essential Medicines List. It is also used topically for reduction of unwanted facial hair in women (not described here).

Pharmacokinetics

Pharmacokinetic parameters for intravenous eflornithine in adult patients with African trypanosomiasis. Data reported for both sexes, typical adult weight range, with normal renal function.

References

1. Amilon, C, et al., & Jansson-Löfmark, R (2022). Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. The AAPS journal 24(3) 48–None. DOI:10.1208/s12248-022-00693-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35338410

2. Johansson, CC, et al., & Jansson-Löfmark, R (2013). Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. Journal of pharmacokinetics and pharmacodynamics 40(1) 117–128. DOI:10.1007/s10928-012-9293-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/23307171

Revisions

• 06/2025 initial generated model